➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Johnson and Johnson
Baxter
McKinsey
Mallinckrodt

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

FOLLISTIM AQ Drug Profile


Email this page to a colleague

« Back to Dashboard

UNDER DEVELOPMENT

Which patents cover Follistim Aq, and when can biosimilar versions of Follistim Aq launch?

Follistim Aq is a drug marketed by Organon Usa Inc and is included in two BLAs.

The biologic ingredient in FOLLISTIM AQ is follitropin alfa/beta. A full profile is posted on the follitropin alfa/beta profile page.

DrugPatentWatch® Biosimilar and Interchangeable Outlook for Follistim Aq

Indicators of Biosimilar Launch

Under Development

  Try it Free

Summary for Tradename: FOLLISTIM AQ
Recent Clinical Trials for FOLLISTIM AQ

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Ferring PharmaceuticalsPhase 2
Center for Human ReproductionPhase 1/Phase 2
Michigan Reproductive MedicinePhase 4

See all FOLLISTIM AQ clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FOLLISTIM AQ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FOLLISTIM AQ Derived from Company Disclosures

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23 ⤷  Try it Free Genzyme Corporation (Cambridge, MA) 2015-06-16 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23 ⤷  Try it Free Akzo Nobel, N.V. (Arnhem, NL) 2017-01-15 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23 ⤷  Try it Free Ares Trading S.A. (Aubonne, CH) 2018-07-23 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 001 2004-03-23 ⤷  Try it Free Ares Trading S.A. (Aubonne, CH) 2018-07-23 DISCN company
Organon Usa Inc FOLLISTIM AQ follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021211 002 2004-03-23 ⤷  Try it Free Genzyme Corporation (Cambridge, MA) 2015-06-16 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

3) Low Certainty: US Patents for FOLLISTIM AQ Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for FOLLISTIM AQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122010000011 Germany ⤷  Try it Free PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
SPC/GB01/030 United Kingdom ⤷  Try it Free PRODUCT NAME: RECOMBINANT CHORIOGONADOTROPIN ALFA; REGISTERED: UK EU/1/00/165/001-006 20010202
91655 Luxembourg ⤷  Try it Free 91655, EXPIRES: 20230113
SZ 13/2001 Austria ⤷  Try it Free PRODUCT NAME: LUTROPIN ALFA
C960004 Netherlands ⤷  Try it Free PRODUCT NAME: RECOMBINANT HUMAAN FOLLIKELSTIMULEREND HORMOON; REGISTRATION NO/DATE: EU/1/95/001/001 - EU/1/95/001/016 19951020
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Johnson and Johnson
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.